BENAZEPRIL tablet, coated BENAZEPRIL HYDROCHLORIDE tablet, coated

Χώρα: Ηνωμένες Πολιτείες

Γλώσσα: Αγγλικά

Πηγή: NLM (National Library of Medicine)

Δραστική ουσία:

BENAZEPRIL HYDROCHLORIDE (UNII: N1SN99T69T) (BENAZEPRILAT - UNII:JRM708L703)

Διαθέσιμο από:

Direct_Rx

Οδός χορήγησης:

ORAL

Τρόπος διάθεσης:

PRESCRIPTION DRUG

Θεραπευτικές ενδείξεις:

Benazepril hydrochloride tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from

Περίληψη προϊόντος:

Benazepril hydrochloride tablets, USP, 5 mg, are round, white, film-coated tablets, debossed “S” on one side and “341” on the other side, packaged as follows: bottle of 100 tablets (with desiccant) Benazepril hydrochloride tablets, USP, 10 mg, are round, red, film-coated tablets, debossed “S” on one side and “342” on the other side, packaged as follows: bottle of 100 tablets (with desiccant) bottle of 500 tablets (with desiccant) Benazepril hydrochloride tablets, USP, 20 mg, are round, grey, film-coated tablets, debossed “S” on one side and “343” on the other side, packaged as follows: bottle of 100 tablets (with desiccant) bottle of 500 tablets (with desiccant) Benazepril hydrochloride tablets, USP, 40 mg, are round, blue, film-coated tablets, debossed “S” on one side and “344” on the other side, packaged as follows: bottle of 100 tablets (with desiccant) bottle of 500 tablets (with desiccant) Store at 20-25°C (68-77°F) [See USP Controlled Room Temperature]. Protect from moisture. Dispense in tight container (USP). Distributed by: Solco Healthcare US, LLC Cranbury, NJ 08512, USA Manufactured by: Zhejiang Huahai Pharmaceutical Co., Ltd. Xunqiao, Linhai, Zhejiang 317024, China Revised: 12/2015 07713-04

Καθεστώς αδειοδότησης:

Abbreviated New Drug Application

Αρχείο Π.Χ.Π.

BENAZEPRIL- BENAZEPRIL TABLET, COATED
BENAZEPRIL HYDROCHLORIDE- BENAZEPRIL HYDROCHLORIDE TABLET, COATED
DIRECT_RX
----------
BENAZEPRIL
Benazepril hydrochloride tablets are indicated for the treatment of
hypertension, to
lower blood pressure. Lowering blood pressure reduces the risk of
fatal and nonfatal
cardiovascular events, primarily strokes and myocardial infarctions.
These benefits have
been seen in controlled trials of antihypertensive drugs from a wide
variety of
pharmacologic classes including the class to which this drug
principally belongs.
Control of high blood pressure should be part of comprehensive
cardiovascular risk
management, including, as appropriate, lipid control, diabetes
management,
antithrombotic therapy, smoking cessation, exercise, and limited
sodium intake. Many
patients will require more than one drug to achieve blood pressure
goals. For specific
advice on goals and management, see published guidelines, such as
those of the
National High Blood Pressure Education Program’s Joint National
Committee on
Prevention, Detection, Evaluation, and Treatment of High Blood
Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic
classes and with
different mechanisms of action, have been shown in randomized
controlled trials to
reduce cardiovascular morbidity and mortality, and it can be concluded
that it is blood
pressure reduction, and not some other pharmacologic property of the
drugs, that is
largely responsible for those benefits. The largest and most
consistent cardiovascular
outcome benefit has been a reduction in the risk of stroke, but
reductions in myocardial
infarction and cardiovascular mortality also have been seen regularly.
Elevated systolic or diastolic pressure causes increased
cardiovascular risk, and the
absolute risk increase per mmHg is greater at higher blood pressures,
so that even
modest reductions of severe hypertension can provide substantial
benefit. Relative risk
reduction from blood pressure reduction is similar across populations
with varying